Which has stronger valuation and earnings, COCP or INKT?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cocrystal Pharma N/A N/A -$8.83M -$0.73 N/A MiNK Therapeutics N/A N/A -$12.49M -$2.84 N/A

Is COCP or INKT more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -150.61% -97.86% MiNK Therapeutics N/A N/A -118.57%

Which has stronger valuation & earnings, COCP or PDSB?

PDS Biotechnology is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cocrystal Pharma N/A N/A -$8.83M -$0.73 N/A PDS Biotechnology N/A N/A -$34.50M -$0.67 N/A

Is COCP or PDSB more profitable?

Cocrystal Pharma's return on equity of -150.61% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -150.61% -97.86% PDS Biotechnology N/A -346.02% -102.36%

Is HYPD or COCP more profitable?

Hyperion DeFi's return on equity of -91.59% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Hyperion DeFi N/A -91.59% -73.08% Cocrystal Pharma N/A -150.61% -97.86%

Do analysts prefer COCP or GMTX?

Cocrystal Pharma presently has a consensus price target of $6.00, indicating a potential upside of 494.06%. Given Cocrystal Pharma's stronger consensus rating and higher possible upside, research analysts plainly believe Cocrystal Pharma is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, COCP or GMTX?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cocrystal Pharma N/A N/A -$8.83M -$0.73 N/A Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A

Is COCP or GMTX more profitable?

Gemini Therapeutics' return on equity of -38.78% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -150.61% -97.86% Gemini Therapeutics N/A -38.78% -35.88%

Which has stronger valuation and earnings, COCP or DWTX?

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cocrystal Pharma N/A N/A -$8.83M -$0.73 N/A Dogwood Therapeutics N/A N/A -$34.26M -$10.60 N/A

Is COCP or DWTX more profitable?

Dogwood Therapeutics' return on equity of -108.57% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -150.61% -97.86% Dogwood Therapeutics N/A -108.57% -30.28%

Cocrystal Pharma (COCP) Competitors

$1.01 -0.01 (-0.98%)

Closing price 04:00 PM Eastern

Extended Trading

$1.00 -0.01 (-0.99%)

As of 05:05 PM Eastern

Compare

COCP vs. INKT, PDSB, HYPD, GMTX, and DWTX

Should you buy Cocrystal Pharma stock or one of its competitors? MarketBeat compares Cocrystal Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cocrystal Pharma include MiNK Therapeutics (INKT), PDS Biotechnology (PDSB), Hyperion DeFi (HYPD), Gemini Therapeutics (GMTX), and Dogwood Therapeutics (DWTX). These companies are all part of the "pharmaceutical products" industry.

How does Cocrystal Pharma compare to MiNK Therapeutics?

Cocrystal Pharma (NASDAQ:COCP) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

6.7% of Cocrystal Pharma shares are held by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are held by institutional investors. 39.4% of Cocrystal Pharma shares are held by company insiders. Comparatively, 22.5% of MiNK Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, MiNK Therapeutics had 2 more articles in the media than Cocrystal Pharma. MarketBeat recorded 3 mentions for MiNK Therapeutics and 1 mentions for Cocrystal Pharma. MiNK Therapeutics' average media sentiment score of 0.67 beat Cocrystal Pharma's score of 0.29 indicating that MiNK Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
MiNK Therapeutics	Positive

Cocrystal Pharma has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

Cocrystal Pharma presently has a consensus price target of $6.00, indicating a potential upside of 494.06%. MiNK Therapeutics has a consensus price target of $35.00, indicating a potential upside of 187.83%. Given Cocrystal Pharma's higher possible upside, equities analysts clearly believe Cocrystal Pharma is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A

MiNK Therapeutics' return on equity of 0.00% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
MiNK Therapeutics	N/A	N/A	-118.57%

Summary

Cocrystal Pharma beats MiNK Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Cocrystal Pharma compare to PDS Biotechnology?

Cocrystal Pharma (NASDAQ:COCP) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

6.7% of Cocrystal Pharma shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 39.4% of Cocrystal Pharma shares are held by company insiders. Comparatively, 9.2% of PDS Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Cocrystal Pharma and Cocrystal Pharma both had 1 articles in the media. PDS Biotechnology's average media sentiment score of 1.87 beat Cocrystal Pharma's score of 0.29 indicating that PDS Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
PDS Biotechnology	Very Positive

Cocrystal Pharma has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market.

Cocrystal Pharma's return on equity of -150.61% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
PDS Biotechnology	N/A	-346.02%	-102.36%

Cocrystal Pharma currently has a consensus price target of $6.00, suggesting a potential upside of 494.06%. PDS Biotechnology has a consensus price target of $9.00, suggesting a potential upside of 749.06%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe PDS Biotechnology is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

PDS Biotechnology is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

Summary

PDS Biotechnology beats Cocrystal Pharma on 7 of the 12 factors compared between the two stocks.

How does Cocrystal Pharma compare to Hyperion DeFi?

Hyperion DeFi (NASDAQ:HYPD) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

In the previous week, Hyperion DeFi had 4 more articles in the media than Cocrystal Pharma. MarketBeat recorded 5 mentions for Hyperion DeFi and 1 mentions for Cocrystal Pharma. Hyperion DeFi's average media sentiment score of 0.75 beat Cocrystal Pharma's score of 0.29 indicating that Hyperion DeFi is being referred to more favorably in the media.

Company	Overall Sentiment
Hyperion DeFi	Positive
Cocrystal Pharma	Neutral

25.8% of Hyperion DeFi shares are owned by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are owned by institutional investors. 7.5% of Hyperion DeFi shares are owned by insiders. Comparatively, 39.4% of Cocrystal Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Hyperion DeFi currently has a consensus target price of $5.65, indicating a potential upside of 124.21%. Cocrystal Pharma has a consensus target price of $6.00, indicating a potential upside of 494.06%. Given Cocrystal Pharma's higher probable upside, analysts clearly believe Cocrystal Pharma is more favorable than Hyperion DeFi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Hyperion DeFi's return on equity of -91.59% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
Cocrystal Pharma	N/A	-150.61%	-97.86%

Hyperion DeFi has a beta of 2.47, suggesting that its stock price is 147% more volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market.

Cocrystal Pharma has lower revenue, but higher earnings than Hyperion DeFi. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810K	47.16	-$45.31M	-$9.95	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A

Summary

Hyperion DeFi beats Cocrystal Pharma on 10 of the 14 factors compared between the two stocks.

How does Cocrystal Pharma compare to Gemini Therapeutics?

Cocrystal Pharma (NASDAQ:COCP) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

In the previous week, Cocrystal Pharma had 1 more articles in the media than Gemini Therapeutics. MarketBeat recorded 1 mentions for Cocrystal Pharma and 0 mentions for Gemini Therapeutics. Cocrystal Pharma's average media sentiment score of 0.29 beat Gemini Therapeutics' score of 0.00 indicating that Cocrystal Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
Gemini Therapeutics	Neutral

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Gemini Therapeutics' return on equity of -38.78% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Cocrystal Pharma presently has a consensus price target of $6.00, indicating a potential upside of 494.06%. Given Cocrystal Pharma's stronger consensus rating and higher possible upside, research analysts plainly believe Cocrystal Pharma is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cocrystal Pharma has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market.

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Cocrystal Pharma beats Gemini Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Cocrystal Pharma compare to Dogwood Therapeutics?

Cocrystal Pharma (NASDAQ:COCP) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

Cocrystal Pharma has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market.

Dogwood Therapeutics' return on equity of -108.57% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

Cocrystal Pharma currently has a consensus price target of $6.00, suggesting a potential upside of 494.06%. Dogwood Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 700.00%. Given Dogwood Therapeutics' higher probable upside, analysts clearly believe Dogwood Therapeutics is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Dogwood Therapeutics had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 2 mentions for Dogwood Therapeutics and 1 mentions for Cocrystal Pharma. Dogwood Therapeutics' average media sentiment score of 1.43 beat Cocrystal Pharma's score of 0.29 indicating that Dogwood Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
Dogwood Therapeutics	Positive

Summary

Dogwood Therapeutics beats Cocrystal Pharma on 8 of the 11 factors compared between the two stocks.

Get Cocrystal Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COCP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COCP vs. The Competition

Export

Metric	Cocrystal Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.93M	$3.28B	$6.43B	$11.71B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-1.38	19.00	24.49	23.62
Price / Sales	N/A	290.52	500.93	104.92
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	2.20	8.00	10.43	6.71
Net Income	-$8.83M	$23.89M	$3.56B	$337.26M
7 Day Performance	-4.72%	-3.48%	-1.37%	-1.39%
1 Month Performance	-29.86%	1.04%	0.87%	1.17%
1 Year Performance	-37.27%	34.40%	19.41%	22.63%

Cocrystal Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COCP Cocrystal Pharma	2.8646 of 5 stars	$1.01 -1.0%	$6.00 +494.1%	-38.2%	$13.93M	N/A	N/A	10	Analyst Upgrade Gap Up
INKT MiNK Therapeutics	3.5133 of 5 stars	$11.99 -3.2%	$35.00 +192.0%	+62.6%	$60.78M	N/A	N/A	30	Gap Up
PDSB PDS Biotechnology	3.5283 of 5 stars	$1.19 +3.9%	$9.00 +659.5%	-39.8%	$60.28M	N/A	N/A	20
HYPD Hyperion DeFi	4.1563 of 5 stars	$3.70 -4.2%	$5.88 +58.9%	-40.0%	$58.51M	$1.04M	N/A	40	Analyst Forecast Gap Down
GMTX Gemini Therapeutics	N/A	$71.97 +3.4%	N/A	+31.5%	$58.49M	N/A	N/A	30	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COCP) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cocrystal Pharma (COCP) Competitors

COCP vs. INKT, PDSB, HYPD, GMTX, and DWTX

How does Cocrystal Pharma compare to MiNK Therapeutics?

Summary

How does Cocrystal Pharma compare to PDS Biotechnology?

Summary

How does Cocrystal Pharma compare to Hyperion DeFi?

Summary

How does Cocrystal Pharma compare to Gemini Therapeutics?

Summary

How does Cocrystal Pharma compare to Dogwood Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCP vs. The Competition

Cocrystal Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cocrystal Pharma (COCP) Competitors

COCP vs. INKT, PDSB, HYPD, GMTX, and DWTX

How does Cocrystal Pharma compare to MiNK Therapeutics?

Do institutionals & insiders have more ownership in COCP or INKT?

Does the media favor COCP or INKT?

Which has more volatility and risk, COCP or INKT?

Do analysts rate COCP or INKT?

Which has stronger valuation and earnings, COCP or INKT?

Is COCP or INKT more profitable?

Summary

How does Cocrystal Pharma compare to PDS Biotechnology?

Do institutionals and insiders hold more shares of COCP or PDSB?

Does the media favor COCP or PDSB?

Which has more risk & volatility, COCP or PDSB?

Is COCP or PDSB more profitable?

Do analysts rate COCP or PDSB?

Which has stronger valuation & earnings, COCP or PDSB?

Summary

How does Cocrystal Pharma compare to Hyperion DeFi?

Does the media refer more to HYPD or COCP?

Do institutionals and insiders believe in HYPD or COCP?

Do analysts rate HYPD or COCP?

Is HYPD or COCP more profitable?

Which has more risk and volatility, HYPD or COCP?

Which has higher valuation and earnings, HYPD or COCP?

Summary

How does Cocrystal Pharma compare to Gemini Therapeutics?

Does the media prefer COCP or GMTX?

Which has preferable earnings and valuation, COCP or GMTX?

Is COCP or GMTX more profitable?

Do analysts prefer COCP or GMTX?

Which has more risk & volatility, COCP or GMTX?

Do institutionals and insiders believe in COCP or GMTX?

Summary

How does Cocrystal Pharma compare to Dogwood Therapeutics?

Which has more risk & volatility, COCP or DWTX?

Is COCP or DWTX more profitable?

Which has stronger valuation and earnings, COCP or DWTX?

Do analysts rate COCP or DWTX?

Do insiders & institutionals have more ownership in COCP or DWTX?

Does the media refer more to COCP or DWTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCP vs. The Competition

Cocrystal Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools